COVID-19 Pandemic: Missed Diagnoses & Rising CKD – What Pharmacists Need to Know
- The COVID-19 pandemic continues to cast a long shadow over healthcare, with recent data revealing significant disruptions in the diagnosis of numerous conditions.
- Researchers at King’s College London analyzed anonymized data from over 29 million individuals, examining trends from April 2016 through November 2024.
- The study utilized data from the OpenSAFELY-TTP platform, a system linking primary and secondary care records from general practices across England.
The COVID-19 pandemic continues to cast a long shadow over healthcare, with recent data revealing significant disruptions in the diagnosis of numerous conditions. While depression diagnoses have been most notably affected – with nearly one-third fewer diagnoses than expected compared to pre-pandemic trends – a new study published in the British Medical Journal (BMJ) highlights broader, persistent impacts on long-term condition diagnoses across England.
Researchers at King’s College London analyzed anonymized data from over 29 million individuals, examining trends from April 2016 through November 2024. The findings indicate that diagnosis rates for several major conditions remain below pre-pandemic levels, raising concerns about delayed care and potential worsening of health outcomes. The study underscores the potential for real-time, anonymized data to transform disease monitoring and identify inequities in healthcare delivery.
Study Design and Data Sources
The study utilized data from the OpenSAFELY-TTP platform, a system linking primary and secondary care records from general practices across England. This dataset, while varying in coverage by region, is considered broadly representative of the English population. Researchers compared observed post-COVID-19 diagnosis rates with expected rates projected from pre-pandemic patterns using statistical modeling.
Condition-Specific Trends: A Mixed Picture
The analysis revealed a complex picture, with some conditions experiencing more significant diagnostic delays than others. Depression showed the largest decline, at 27.7%, followed by asthma, chronic obstructive pulmonary disease (COPD) and osteoporosis. Interestingly, diagnoses of chronic kidney disease (CKD) increased above expectations by 34.8%, representing approximately 359,000 additional cases.
The decline in depression diagnoses was particularly pronounced among adults aged 20 to 39 years of White or mixed ethnicity. According to co-study author Sam Norton, professor of medical statistics at King’s College London, this trend was unexpected, as rates had shown some recovery in late 2021 before falling sharply again in 2022. This finding contrasts with a substantial increase in disability benefit claims for mental health conditions, suggesting that the decline in formal diagnoses may not reflect an improvement in mental health.
The increase in CKD diagnoses may be attributable to several factors, including increased testing, greater awareness following guideline changes, and the introduction of new treatments. Mark Russell, PhD, consultant rheumatologist and epidemiologist at King’s College London, also suggested that the pandemic itself may have contributed to an increase in CKD, potentially through the direct effects of COVID-19 infection or delays in diagnosing related conditions like diabetes.
Unequal Recovery and Socioeconomic Disparities
The study also highlighted disparities in recovery rates based on ethnicity and socioeconomic status. While dementia diagnoses returned to expected levels for White individuals and those living in less deprived areas, they remained low among other ethnic groups and individuals in more deprived communities. This suggests that the pandemic’s impact on healthcare access and diagnosis has not been uniform across all populations.
Impact of the Pandemic and Healthcare Pressures
The study authors attribute the observed trends to a combination of factors, including growing pressures on the National Health Service (NHS), delays in formal diagnoses, and increased access to mental health support outside of traditional diagnostic pathways. Expanded access to psychological therapies, particularly through self-referral, may account for some of the decline in formal depression diagnoses. Pandemic-related disruptions and backlogs in diagnostic testing likely contributed to reduced diagnoses of asthma, COPD, and osteoporosis.
Implications for Healthcare Professionals
These findings underscore the importance of proactive healthcare monitoring and addressing disparities in access to care. The study demonstrates the value of routinely collected health data for tracking disease trends in near real-time, which can inform public health interventions and improve disease detection.
While the provided search results do not specifically address the role of pharmacists, the observed trends suggest an increasingly important role for these healthcare professionals in identifying potential gaps in care. Patients may be receiving treatment for symptoms without a formal diagnosis, or may not yet be engaged with the healthcare system. Pharmacists are well-positioned to recognize warning signs, support appropriate referrals, and reinforce evidence-based screening and monitoring.
The impact of the COVID-19 pandemic on healthcare systems continues to unfold. Ongoing monitoring of diagnosis rates and proactive efforts to address disparities will be crucial to mitigating the long-term consequences of this disruption.